1. Scrip
  3. >>Anti-infective

Pfizer To Take Zinplava Rival Into Phase III For C Diff

 
• By Alexandra Shimmings

Pfizer will start a Phase III trial for its Clostridium difficile vaccine by the middle of the year, taking aim at the chinks in the armour of Merck & Co’s recently approved Zinplava, but it still trails its rival from Sanofi.

Clostridium
Clostridium

Top-line data for Pfizer Inc.’s investigational vaccine PF-06425090 for the prevention of Clostridium difficile infection from a pre-planned interim analysis are strong enough to warrant taking the product into a Phase III trial due to start in the first half, the company says.

Pfizer is spying territory currently occupied by Merck & Co. Inc.’s Zinplava (bezlotoxumab) which was finally approved by the FDA in October despite some concerns by its Antimicrobial Drugs Advisory Committee at its meeting in June, and also recently received EU approval on Jan. 18. (Also see "Merck & Co Expands C Diff Franchise With US Zinplava Approval" - Scrip, 24 October, 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.